SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the approaching FDA decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders weighing the companys amended application and longer-term upper-limb data alongside recent FDA discussion of flexibility in rare-disease reviews. Many are bullish and read commercial hiring as a sign of launch preparation, while skeptics stress that approval is uncertain given the earlier negative review and debate over the evidence; some also cite Inovios separate FDA approval as a positive sentiment signal.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A push to a fresh 52-week high is drawing attention ahead of an expected Q3 earnings update, while traders debate whether the rally reflects business momentum, short-covering, or speculation about an unconfirmed buyout.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing treatment for recurrent respiratory papillomatosis has raised concerns about new competition for Precigens PAPZIMEOS. Traders debate the threat: some see a serious challenge, while others argue Precigen retains an advantage from its commercial head start and full approval, and view the selloff as an overreaction.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas stronger-than-expected quarterly results and raised outlook, alongside growing interest in identity security for AI agents, have driven a sharp rally. Traders are divided between seeing durable cybersecurity demand and warning that the move has outrun the companys growth, with valuation concerns and profit-taking weighing on shares.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicare reimbursement for DefenCath could decline after early 2027 has fueled concerns about pricing and CorMedixs largest revenue driver. Traders are divided: some see the comments as a serious commercial risk, while others argue DaVitas outlook is preliminary and point to CMSs reimbursement estimate as a counterweight.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

MLYS is under pressure amid concerns that the slow early commercial ramp for AstraZenecas competing hypertension drug could signal a challenging launch and weaker near-term sales prospects for lorundrostat. Traders disagree on whether that undermines Mineralyss commercial outlook, with some emphasizing the upcoming FDA decision and clinical data while others question its ability to compete independently.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff and fresh lows ahead of its earnings report are driving attention, with analyst price-target cuts and concerns about advertising demand adding pressure. Traders are split between viewing the decline as excessive given the companys growth and profitability, and worrying that weaker ad-market signals or an earnings disappointment could prolong the slide.

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,396.41. The last known price of BNB is 698.79071116 USD and is down -6.08 over the last 24 hours. It is currently trading on 3523 active market(s) with $4,017,835,584.29 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

A reported major Binance security breach, with withdrawals temporarily suspended and billions in crypto reportedly affected, is driving attention to BNB and broader crypto-market concerns. Traders are debating whether the incident threatens trust in Binance and warrants further selling, while others view the selloff as an overreaction; claims of an inside job remain speculation.

Permian Resources Corp. is an oil and natural gas company, which focuses on returns to stakeholders through the responsible acquisition, optimization and development of crude oil and associated liquids-rich natural gas reserves. The company was founded on December 18, 2025 and is headquartered in Midland, TX.

Permian Resources Holdings Inc. - Ordinary Shares - Class A

Permian Resources Corp - Ordinary Shares - Class A

Permian Resources is being discussed amid volatile crude prices and shifting Middle East supply risks, especially tensions and shipping disruptions around the Strait of Hormuz. Traders debate why PR often fails to track oils moves, while some point to the companys production growth, guidance and dividends as support for a longer-term bullish view.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centruss steep selloff is the dominant topic, with traders citing share dilution and the cost and execution risks of expanding enrichment capacity, alongside weakness across nuclear stocks. Bulls point to its strategic U.S. HALEU supply role and government contracts as long-term support, while others question the valuation and whether the decline has further to run.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

Invesco Exchange-Traded Fund Trust - Invesco Biotechnology & Genome ETF

Why Did MNKD Stock Jump Over 7% In Pre-Market Today?

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>The revised label provides clearer starting-dose guidance for adult patients switching from multiple daily injections or insulin pump therapy.</li><li>The update is supported by clinical results from the Dose Optimization study and the INHALE-3 trial.</li><li>Previously, MannKind filed a supplemental FDA application to expand Afrezza’s use to patients aged four to 17, with a decision anticipated by May 29, 2026.</li></ul>Shares of MannKind Corp. (MNKD) gained more than 7% in pre-market trading on Monday after the company announced that the U.S. Food and Drug Administration (FDA) approved an update to the prescribing information for Afrezza, its inhaled mealtime insulin used to improve glycemic control in adult patients with diabetes mellitus.The revised label provides clearer starting-dose guidance for adult patients switching from multiple daily injections or insulin pump therapy. The update is supported by clinical results from the Dose Optimization study and the INHALE-3 trial, which showed significantly improved post-meal glucose control after conversion to Afrezza, as recommended by the new dosing recommendations.“We expect that this label update will help support healthcare providers by providing clearer starting dose guidance when transitioning patients to inhaled insulin from subcutaneous mealtime insulin—whether injections or insulin pumps. We believe this refinement to the label helps support appropriate initiation of therapy while reinforcing Afrezza’s established clinical profile,” said Kevin Kaiserman, Senior Vice President, Therapeutic Area Head, Diabetes at MannKind Corporation.&nbsp;<h2 class="st-heading-2">Q3 Revenue Boosted By Afrezza Sales</h2>In November, the company posted a 17% increase in third-quarter (Q3) total revenue to $82.13 million, driven by strong growth in sales of its Afrezza inhaled insulin. Afrezza revenue climbed 23% to $18.5 million, supported by higher pricing and rising demand, while royalty income rose to $33.3 million.MannKind also submitted a supplemental application to the FDA seeking approval of Afrezza for patients aged four to 17. A regulatory decision is expected by May 29, 2026.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/MNKD">MNKD</a> on Stocktwits remained in the ‘bullish’ zone over the past 24 hours, accompanied by ‘high’ message volumes. MNKD was among the top trending tickers at the time of writing.<figure class="image"><img src="https://news.stocktwits-cdn.com/MNKD_jpg_fd37ecdc2d.webp" alt="MNKD.jpg" width="930" height="85"><figcaption>MNKD's Sentiment Meter and Message Volumes at Premarket on Jan. 26, 2026 | Source: Stocktwits</figcaption></figure>Meanwhile, one user didn’t see the FDA update as a major catalyst.<stembedurl>https://stocktwits.com/firefox2778/message/642859216</stembedurl>The stock has declined around 4.7% year-to-date and over 10.5% in the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ag-asml-hl-stocks-soar-silver-prices-record-high-110/cmy78kuR4WC">AG, ASM, HL Stocks Soar Pre-Market As Silver Blasts Past $110</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mannkind Corp and the company's inhalable insulin product. Company employee demonstrating how the device is used. (Photo by Lawrence K. Ho/Los Angeles Times via Getty Images)

The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus.

MNKD Stock Gets A Pre-Market Boost From FDA Label Revision For Afrezza

iShares Russell 2000 ETF

Mannkind Corp

Invesco Dynamic Biotechnology & Genome ETF

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

PBE Invesco Dynamic Biotechnology & Genome ETF

Fundamentals

Latest PBE News